OBJECTIVE： To provide reference for pharmacists to participate in the management of chronic disease. METHODS： A total of 259 patients with chronic airway disease [included asthma and chronic obstructive pulmonary disease （COPD）] met the inclusion criteria were selected from our hospital and 5 community health care centers of medical consortium. These patients received medication safety assessment management， which was led by clinical pharmacists of our hospital with the participation of community pharmacists， including medication safety comprehensive evaluation and risk classification management， follow-up and medication guidance， integrated prescriptions checking， establishment of shared database. 1 years after the implementation， the effectiveness were evaluated by score the relatived indicators in related groups. RESULTS： After a year of the management mode practice， compared with before intervention， the patients’ safety medication cognitive ability score in high-risk and low-risk group increased from （4.49±1.26） and （7.31±1.01） to （5.40±1.56） and （7.44±0.91）； medication adherence score increased from （4.96±1.21） and （7.08±1.24） to （6.66±1.08） and （7.38±0.98）； ACT score from asthma patients increased from （16.15±2.58） and （21.15±1.03） to （16.80±2.57） and （21.64±1.55）； CAT score from COPD patients decreased from （25.51±4.07） and （14.90±3.95） to （24.20±3.96） and （13.80±4.08）； the rate of irrational prescription effective identification and intervention by pharmacists increased from 3.6％ and 1.4％ to 9.4％ and 7.6％， respectively. All the differences above were statistically significant （P＜0.05）. CONCLUSIONS： The participation of pharmacists in long-term medication safety assessment management for chronic airway disease patients can improve patients’ safety medication cognitive ability， medication adherence， disease control and the pharmacists’ ability of irrational drug use identification and intervention.